What Syncromune Inc.’s SYNC-T data reveals about the future of combination immunotherapy
Discover how Syncromune Inc.’s SYNC-T data could reshape combination immunotherapy. Find out what this means for cancer treatment innovation.
Privo’s PRV131 enters first-in-human dosing: Can injectable cisplatin change oral cancer surgery?
Privo Technologies has officially initiated dosing in a Phase 1/2 trial evaluating PRV131, its nanoengineered intratumoral cisplatin injectable, for the treatment of T1–T3 oral squamous cell carcinoma (OSCC). The trial, designated Arm 3 of the CLN-004 study, will explore PRV131 as a neoadjuvant therapy aimed at shrinking tumors before surgery. The announcement marks a pivotal […]
Could NanOlogy’s targeted intratumoral cisplatin rewrite the outlook for DIPG in children?
NanOlogy, LLC, a Texas-based clinical-stage oncology company, has announced the launch of a drug development program focused on diffuse intrinsic pontine glioma, known as DIPG, a universally fatal pediatric brainstem tumor. The company is advancing Large Surface Area Microparticle Cisplatin, or LSAM-cisplatin, designed for stereotactic intratumoral administration in children. Investigational New Drug–enabling studies are underway, […]